Pfizer donates $1M to San Diego's Moores Cancer Center for early detection initiative
UC San Diego's Moores Cancer Center has received a $1 million donation from pharmaceutical giant Pfizer to support early ...
Oncology Nursing News3d
Vepdegestrant Meets PFS End Point for Metastatic Breast Cancer Subtype
Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...
Breast Cancer Market to Witness Upsurge in Growth by 2032, According to DelveInsight
The Breast Cancer market is undergoing significant expansion, driven by increasing disease prevalence and the introduction of innovative therapeutic options from companies such as ...
PMLive9d
Pfizer/Arvinas’ vepdegestrant shows promise in phase 3 breast cancer study
The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...
UC San Diego Today1d
UC San Diego Moores Cancer Center Receives $1M Donation from Pfizer for Early Cancer Detection
Funding will support Moores Cancer Center’s efforts to develop a unique, large-scale program to drive early detection and ...
Labiotech.eu9d
Breast cancer treatments heat up: Five therapies poised to transform patient outcomes
Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...
Medscape3d
Shorter Radiotherapy, Fewer Toxicities in Breast Cancer?
Early toxicities associated with a 3-week hypofractionated radiotherapy regimen do not raise initial safety concerns in women ...
Applied Clinical Trials Online4d
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...